NCT00943592View on ClinicalTrials.gov

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2011

Study Completion Date

November 30, 2013

Conditions
Advanced Hematologic MalignanciesLeukemiaPreleukemia
Interventions
DRUG

Clofarabine

Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).

DRUG

Melphalan

Doses ranging from 100 to 140 mg/m2

DRUG

Campath

20mg/d x5

PROCEDURE

Stem Cell Transplant

Infusion of donor, bone marrow and auto.

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00943592 - Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter